Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER
SAN DIEGO, Dec. 30, 2021 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP):
First of all I would like to wish all our shareholders a happy holiday season. It has been a long year with many challenges and many successes.
When I returned to Regen on March 23, 2021 in order to serve as Chairman and Chief Executive Officer I found myself at the helm of a company on the verge of collapse. We were behind in bills, at risk of losing patent protection on valuable IP, and delinquent in our SEC filing obligations. Worse of all we were being sued by Chemdiv-our Contract Research Organization- in a complaint seeking damages of $1,200,000 which also threatened our ownership rights to valuable intellectual property
As the year progressed we faced the challenges that lay before us and conquered them. Regen has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office, settled its lawsuit with Chemdiv, been issued several new patents, entered into two non-related party licensing agreements and became current in its SEC filing obligations eliminating the risk that the public trading market for both the common and Series A preferred shares would disappear.
Becoming current in our SEC reporting obligations after such a long delinquency was a significant achievement. Recent amendments to SEC Rule 15c2-11 threatened the public trading status of delinquent issuers. Had I not been able to get the Company current there was a real possibility that our shareholders wouldn't be able to trade their shares and the Company's ability to raise capital would be adversely effected.
I have received numerous texts, emails and phone calls regarding our restatement of our third quarter financials.
During the quarter ended June 30, 2021 the Company was paid $1,905,000 in cash and securities resulting from two licenses granted in April, 2021 to Oncology Pharma, Inc. ("ONPH").
Pursuant to the terms and conditions of the licenses granted ONPH became obligated to:
(a) Pay nonrefundable fees of $55,000 and fifty thousand common shares of ONPH no later than April 20, 2021
(b) Pay royalties equal to five percent (5%) of the Net Sales (as Net Sales are defined in the Agreement) of any Licensed Products in a quarter.
Accounting for Revenues from contracts with customers and licensees is governed by Accounting Standard Codification 606 ("ASC 606") issued by the Financial Accounting Standards Board ("FASB").
ASC 606 requires that revenue be recognized as performance obligations are fulfilled. In considering the accounting for revenue generated by the licenses, the Company initially determined that the nonrefundable fees paid were consideration solely for entering into the agreement and thus should be recognized within the quarter in which they were paid.
A subsequent examination in conjunction with the Company's public accountant led us to reconsider this accounting treatment and we determined that -- in order to be compliant with ASC 606- the revenue generated by the payment to the Company of the nonrefundable fees would need to be recognized over the term of the licenses. We arrived at the conclusion that entering into the agreement did not adequately meet the criteria of being "distinct within the context of the contract" from the obligation of granting the license over the term of the contract. None of the abovementioned changes the fact that $1,905,000 in cash and securities was paid to the Company during the quarter ended June 30, 2021 and this payment was nonrefundable.
Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen's shareholders and I expect to identify a contract research organization that will help us move the Company's intellectual propriety towards clinical trials.
During this past year I haven't taken a dime in salary from Regen. The reason for this is because I see our company for all its potential and possibilities and I'm betting on what we have and what we can achieve.
Sincerely,
David R. Koos
Chairman & CEO
Regen BioPharma Inc.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
http://www.regenbiopharmainc.com
View original content:https://www.prnewswire.com/news-releases/regen-biopharma-inc-message-to-the-shareholders-from-the-chairman-and-chief-executive-officer-301452028.html
SOURCE Regen BioPharma, Inc.
(END) Dow Jones Newswires
December 30, 2021 15:41 ET (20:41 GMT)
For those that don't know.....
https://samsungbiologics.com/
Yeah something like 300 billion to invest over next ten years or so. Numbers may not be exact but they got dough to spend
Wonder if this means their(Ichim and Patel) focus is on rgbp more.
https://ih.advfn.com/stock-market/NASDAQ/creative-medical-technol-CELZ/stock-news/86750370/current-report-filing-8-k
You thinking we'll close on the VWAP? Seems to be routine.
I agree with you. I was in Celz believing in the potential and the product, before the split announcement. Am glad I am out . If you have thousands of shares left or got in with thousands you'll be good, if not, eh.
Momentum building for an upwards move?
Was just about to post that. Here is all of it... https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-Year-End-Review-and-Outlook?id=334935
One thing those that are long rgbp know is that they keep on being mentioned with the big boys. There may only be no more than 3-5 otcs out there that have a chance to play with and become a big leaguer. Rgbp is one of them(been following market for 30 plus years).
Awesome consultants and advisors.
Hopefully they still have a relationship with Lilly.
A product(s) desired by many and useful to many. Life saving.
All that said, I hope that we the shareholders benefit(and dont get short changed or even worse, shafted) for believing and financially supporting what could be an awesome story for all.
Couldnt agree more. Have seen those reports go for 3500 plus and are obviously for professionals/ corps to read.
I too wouldnt know wtf it meant.
Hard to tell if this is old or new with as many of these that come out during the year but this is dated Dec 7 and Rgbp is in it with the big guys.
https://www.marketwatch.com/press-release/indoleamine-23-dioxygenase-1-market-2021-global-industry-analysis-trends-market-size-and-forecasts-up-to-2027-with-dominant-sectors-and-countries-data-2021-12-07
Been doing this way too long, RS never, never a good idea in the otc.
And 1:4 takes us to under. 08 far far from nasdaq and nyse req.
As most have said, no need for RS nonsense. Last time I'll speak of it( I'm a man of my word).
Night longs.
I agree something seemed like it was going on at end of day
Dollar says we get news or 8k today. Don't worry I'll pay if I lose.
Thanks, don't have level II or that info
Lowest its been is around 30, may tap that then head up but I'm hoping we are close like you hope
You're welcome
Not sure myself. Seems he leased a property from himself?
I just try and find stuff that pertains to rgbp and let others explain.
REGEN BIOPHARMA INC : Termination of a Material Definitive Agreement, Change in Directors or Principal Officers (form 8-K)
01/22/2020 | 04:08pm
Item 1.02 Termination of a Material Definitive Agreement.
On January 20, 2020 Regen Biopharma, Inc. (the "Company") and BST Partners Inc. agreed that the month to month sublease by and between the Company and BST Partners, Inc. whereby the Company subleased office space from BST Partners, Inc.at 4700 Spring Street, St 304, La Mesa, California 91942 shall terminate as of 1pm Pacific Standard Time on January 22, 2020.
found this, dated Nov15 https://www.chemxpert.in/news/nanosmart-receives-second-fda-orphan-drug-designation-for-treatment-of-pediatric-cancer
From RGBP website to check to see if related
HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
Welcome back Jack.
Dr. Harry Lander, Regen's president and CSO, noted, "Biotechnology companies focused on successful immune-oncology therapies are generally granted trophy value transactions (e.g., deals that have a value in excess of $1 billion). In addition to our intent to create a first-in-class immune checkpoint inhibitor for treating cancers, we also plan to exploit the anti-autoimmune aspects of our small molecules as well. Thus, while we can't anticipate what our valuation will be if our programs pan out, it's good to know we're swimming in the right pool."
Currently CheckPoint Immunology is at the lead optimization phase of its medicinal chemistry program. The Company anticipates that once results of the medicinal chemistry program being conducted by ChemDiv, Inc. are available, we should be in a position to form alliances with large companies interested in NR2F6 inhibition for cancer therapy or NR2F6 activation for treating autoimmune disorders.
Regen BioPharma's Chairman and CEO, David Koos, stated, "In the beginning, Regen's business model was created with the goal of developing intellectual property to a point of attracting large pharmaceutical companies, to participate in maturing Company assets, either by sale, license or co-development. By forming CheckPoint Immunology, we are setting our game plan in place so that as we get further along in our development of small molecule therapies for treating cancer and autoimmune diseases, we can structure a transaction specific to NR2F6-related therapies. The Company has been approached by numerous parties interested in our NR2F6 based therapies. We expect, as we further optimize our small molecule compounds, there should be even greater interest. Hence the reason for creating CheckPoint Immunology is as a pure vehicle for any future NR2F6 transaction."
Wonder if there's still a relationship here?
https://objectivecp.com/our-work/
One has nothing to do with the other jonesin taint.
Its got that smelly smell
If this drops below .0182 support should be found around .0169
The site wants me to subscribe. If you select us patents on section to left and pharmaceuticals section just above it, then scroll down to the ones in parenthesis, select regen biopharma....
U.S. Patent and Trademark Office Releases Regen Biopharma's Patent Application for Reduction of Post-Surgery Cancer Metastasis by Combination of Cannabidiol and NR2F6 Inhibition
PHARMACEUTICAL | Fri 19 Nov 2021Alexandria, Nov. 19 -- U.S. Patent and Trademark Office has released Regen Biopharma's patent application for reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition. Ichim Thomas and Koos David developed the invention. The patent application number is 17/037284. International Patent Cl..
Ill get the link correct.
Is this new? Sorry if it isn't.
https://www.globalipnews.com/assignee
Time to head upward from here, I hope, lol
Found this site with all of RGBP news throughout years. Kind of a timeline...
https://ycharts.com/companies/RGBP/news